{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unspecified+Schizophrenia+Spectrum+and+Other+Psychotic+Disorder",
    "query": {
      "condition": "Unspecified Schizophrenia Spectrum and Other Psychotic Disorder"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1636,
    "total_pages": 164,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unspecified+Schizophrenia+Spectrum+and+Other+Psychotic+Disorder&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T07:52:40.357Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01981759",
      "title": "D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Delusional Disorder"
      ],
      "interventions": [
        {
          "name": "D-Cycloserine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Cognitive Behavioral Therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "68 Years",
        "sex": "ALL",
        "summary": "18 Years to 68 Years"
      },
      "enrollment_count": 58,
      "start_date": "2014-02",
      "completion_date": "2017-10",
      "has_results": true,
      "last_update_posted_date": "2020-03-25",
      "last_synced_at": "2026-07-23T07:52:40.357Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • New York, New York",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01981759"
    },
    {
      "nct_id": "NCT06058702",
      "title": "Genetic Basis of the Risk and Consequences of Cannabis Exposure in Humans",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia",
        "Cannabis Use Disorder"
      ],
      "interventions": [
        {
          "name": "Delta-9-THC Very Low Dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Delta-9-THC Medium Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "21 Years to 60 Years"
      },
      "enrollment_count": 215,
      "start_date": "2024-09-16",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-07-23T07:52:40.357Z",
      "location_count": 1,
      "location_summary": "West Haven, Connecticut",
      "locations": [
        {
          "city": "West Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06058702"
    },
    {
      "nct_id": "NCT05643170",
      "title": "An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Xanomeline and Trospium Chloride Capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Karuna Therapeutics, Inc., a Bristol Myers Squibb company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 4,
      "start_date": "2022-11-08",
      "completion_date": "2023-03-08",
      "has_results": true,
      "last_update_posted_date": "2024-06-12",
      "last_synced_at": "2026-07-23T07:52:40.357Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Louisville, Kentucky • Columbus, Ohio + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Rock Hill",
          "state": "South Carolina"
        },
        {
          "city": "St. George",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05643170"
    },
    {
      "nct_id": "NCT00350883",
      "title": "Cognitive Therapy for Negative Symptoms and Functioning",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "Cognitive Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Treatment as Usual",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 61,
      "start_date": "2006-07",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2012-05-03",
      "last_synced_at": "2026-07-23T07:52:40.357Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00350883"
    },
    {
      "nct_id": "NCT00421954",
      "title": "Open-label Ziprasidone Study for Psychosis Treatment in Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophreniform Disorder",
        "Schizoaffective Disorder",
        "Psychosis",
        "Depressive Disorder, Major",
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Ziprasidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "13 Years to 17 Years"
      },
      "enrollment_count": 8,
      "start_date": "2006-05",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2017-01-13",
      "last_synced_at": "2026-07-23T07:52:40.357Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00421954"
    },
    {
      "nct_id": "NCT00174603",
      "title": "Treatment of Depression With Quetiapine",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depression With Psychotic Features"
      ],
      "interventions": [
        {
          "name": "quetiapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 60,
      "start_date": "2005-08",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2008-01-10",
      "last_synced_at": "2026-07-23T07:52:40.357Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00174603"
    },
    {
      "nct_id": "NCT00272168",
      "title": "The Use of Skills Training to Augment Compensated Work Therapy (CWT)/VI for Veterans With SMI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mental Illness",
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Maryland Program for Vocational Effectiveness",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Supportive Treatment for SMI",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 88,
      "start_date": "2005-10",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2016-06-17",
      "last_synced_at": "2026-07-23T07:52:40.357Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00272168"
    },
    {
      "nct_id": "NCT00325689",
      "title": "Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "Quetiapine or Risperidone + Aripiprazole",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine or Risperidone + placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 323,
      "start_date": "2006-07",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2013-11-08",
      "last_synced_at": "2026-07-23T07:52:40.357Z",
      "location_count": 48,
      "location_summary": "Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 37 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00325689"
    },
    {
      "nct_id": "NCT06923891",
      "title": "An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Xanomeline/Trospium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanguard Research Group",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 172,
      "start_date": "2025-04-16",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2025-04-11",
      "last_synced_at": "2026-07-23T07:52:40.357Z",
      "location_count": 1,
      "location_summary": "Richmond, Texas",
      "locations": [
        {
          "city": "Richmond",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06923891"
    },
    {
      "nct_id": "NCT05601050",
      "title": "Linguistic Predictors of Outcomes in Psychosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Schizophrenia and Related Disorders"
      ],
      "interventions": [
        {
          "name": "There is no intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "15 Years to 40 Years"
      },
      "enrollment_count": 77,
      "start_date": "2021-03-04",
      "completion_date": "2023-03-01",
      "has_results": false,
      "last_update_posted_date": "2023-03-22",
      "last_synced_at": "2026-07-23T07:52:40.357Z",
      "location_count": 1,
      "location_summary": "Glen Oaks, New York",
      "locations": [
        {
          "city": "Glen Oaks",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05601050"
    }
  ]
}